TLP
SNDX icon

Tri Locum Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Tri Locum Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-180,261
Closed -$4.03M – 38
2021
Q1 		$4.03M Buy
180,261
+61,428
+52% +$1.39M 1% 21
2020
Q4 		$2.64M Buy
+118,833
New +$2.46M 0.96% 28

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tri Locum Partners's SNDX Position: Q2 2021 in Review

Tri Locum Partners sold out of Syndax Pharmaceuticals (SNDX) in Q2 2021, closing a stake of 180,261 shares — an estimated $4.03M sold.

Tri Locum Partners first reported a position in SNDX in Q4 2020 and held it in 2 quarters. The position peaked at $4.03M in Q1 2021. 115 funds tracked by Wall St. Rank hold SNDX as of Q2 2021.

  • Tri Locum Partners reported no remaining Syndax Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Tri Locum Partners sold 180,261 Syndax Pharmaceuticals shares in Q2 2021, an estimated $4.03M.
  • Tri Locum Partners first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Tri Locum Partners's Syndax Pharmaceuticals position peaked at $4.03M in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2021.

Based on Tri Locum Partners's 13F filing for Q2 2021, filed 16 Aug 2021.